Michael Engsig
Chief Executive Officer Nykode Therapeutics
Michael joined Nykode Therapeutics in 2017. He is a broadly anchored pharmaceutical professional with extensive experience, from early-stage drug discovery to late-stage development and product launches in biotech and pharma and across all major geographical areas. His career history includes specialist and managerial roles at Takeda and Nycomed. Michael holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from the Copenhagen Business School (CBS).
Seminars
Wednesday 4th March 2026
Session Details to be Announced
12:00 pm
Wednesday 4th March 2026
Panel Discussion: Defining Success in Antigen Specific Immune Tolerance
11:30 am
- What does true success look like in ASIT – single-dose cures, durable remission, or reduced treatment burden?
- How can the field align on shared clinical benchmarks as we move from preclinical to human data
- What lessons can be drawn from broader immunology approaches, such as B cell depletion, allergy learnings and tolerance induction?
- How do current clinical outcomes compare between targeted tolerance and broader immunoregulatory mechanisms?
